Dr. Murray on real-world study of antegrade administration of reverse thermal mitomycin gel for UTUC
Katie Murray, DO, urologic oncologist and assistant professor of Urology at the University of Missouri, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel (Jelmyto) for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube. The study, which was presented at the 2022 AUA Annual Meeting (abstract PD58-06), sought to analyze whether antegrade administration of Jelmyto might decrease some of the comorbidity and complications reported in the pivotal OLYMPUS trial that led to the FDA approval of the treatment.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
